{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:23:25Z","timestamp":1788092605249,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014477","name":"National Health Insurance Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014477","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.amjmed.2022.04.029","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T19:36:27Z","timestamp":1652556987000},"page":"1001-1007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Association of Angiotensin Receptor Blockers with Incident Parkinson Disease in Patients with Hypertension: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-1121","authenticated-orcid":false,"given":"Hsiu-Chen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Fu","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Ling","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3610-9580","authenticated-orcid":false,"given":"Jane Chen-Jui","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yeh","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-8504","authenticated-orcid":false,"given":"Hsiu-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjmed.2022.04.029_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2022.04.029_bib0002","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/S1353-8020(11)70065-7","article-title":"Neuroinflammation in Parkinson's disease","volume":"18","author":"Hirsch","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.amjmed.2022.04.029_bib0003","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12272-019-01133-0","article-title":"Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for Parkinson's disease prevention","volume":"42","author":"Lee","year":"2019","journal-title":"Arch Pharm Res"},{"issue":"1","key":"10.1016\/j.amjmed.2022.04.029_bib0004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13041-017-0340-9","article-title":"Oxidative stress and cellular pathologies in Parkinson's disease","volume":"10","author":"Puspita","year":"2017","journal-title":"Mol Brain"},{"issue":"10","key":"10.1016\/j.amjmed.2022.04.029_bib0005","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.peptides.2011.09.010","article-title":"A new look at the renin-angiotensin system\u2013focusing on the vascular system","volume":"32","author":"Nguyen Dinh Cat","year":"2011","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.amjmed.2022.04.029_bib0006","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1470320309347789","article-title":"The role of the central renin-angiotensin system in Parkinson's disease","volume":"11","author":"Mertens","year":"2010","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.amjmed.2022.04.029_bib0007","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fendo.2013.00158","article-title":"A role for the brain RAS in Alzheimer's and Parkinson's diseases","volume":"4","author":"Wright","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.amjmed.2022.04.029_bib0008","first-page":"67","article-title":"Brain renin-angiotensin system and dopaminergic cell vulnerability","volume":"8","author":"Labandeira-Garc\u00eda","year":"2014","journal-title":"Front Neuroanat"},{"issue":"1","key":"10.1016\/j.amjmed.2022.04.029_bib0009","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1152\/ajpregu.00476.2002","article-title":"Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression","volume":"285","author":"Chabrashvili","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"10.1016\/j.amjmed.2022.04.029_bib0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.nbd.2008.03.003","article-title":"Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS","volume":"31","author":"Rodriguez-Pallares","year":"2008","journal-title":"Neurobiol Dis"},{"issue":"10","key":"10.1016\/j.amjmed.2022.04.029_bib0011","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","article-title":"Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease","volume":"26","author":"Perez-Lloret","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.amjmed.2022.04.029_bib0012","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.neurobiolaging.2006.02.018","article-title":"Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons","volume":"28","author":"Rey","year":"2007","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.1016\/j.amjmed.2022.04.029_bib0013","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1471-4159.2009.05999.x","article-title":"The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease","volume":"109","author":"Joglar","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.amjmed.2022.04.029_bib0014","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ijcard.2016.10.069","article-title":"New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): Focus on cardiovascular and neurological diseases","volume":"227","author":"Mascolo","year":"2017","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2022.04.029_bib0015","doi-asserted-by":"crossref","first-page":"e98961","DOI":"10.1371\/journal.pone.0098961","article-title":"Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"issue":"16 Pt 2","key":"10.1016\/j.amjmed.2022.04.029_bib0016","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"Becker","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.amjmed.2022.04.029_bib0017","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","article-title":"L-type calcium channel blockers and Parkinson disease in Denmark","volume":"67","author":"Ritz","year":"2010","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.amjmed.2022.04.029_bib0018","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/HYPERTENSIONAHA.111.171249","article-title":"Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK Study","volume":"57","author":"Qiu","year":"2011","journal-title":"Hypertension"},{"issue":"3-4","key":"10.1016\/j.amjmed.2022.04.029_bib0019","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000496977","article-title":"Association between hypertension and the risk of Parkinson's disease: a meta-analysis of analytical studies","volume":"52","author":"Chen","year":"2019","journal-title":"Neuroepidemiology"},{"issue":"6","key":"10.1016\/j.amjmed.2022.04.029_bib0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1212\/01.wnl.0000344171.22760.24","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"72","author":"Ascherio","year":"2009","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.amjmed.2022.04.029_bib0021","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/mds.25614","article-title":"Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease","volume":"28","author":"Labandeira-Garcia","year":"2013","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.amjmed.2022.04.029_bib0022","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.410320306","article-title":"Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia","volume":"32","author":"Allen","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.amjmed.2022.04.029_bib0023","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fnana.2014.00152","article-title":"Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update","volume":"8","author":"Brichta","year":"2014","journal-title":"Front Neuroanat"},{"issue":"18","key":"10.1016\/j.amjmed.2022.04.029_bib0024","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","article-title":"Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons","volume":"25","author":"Pacelli","year":"2015","journal-title":"Curr Biol"},{"issue":"2","key":"10.1016\/j.amjmed.2022.04.029_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"10.1016\/j.amjmed.2022.04.029_bib0026","doi-asserted-by":"crossref","first-page":"e13031","DOI":"10.1111\/acel.13031","article-title":"Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease","volume":"18","author":"Trist","year":"2019","journal-title":"Aging Cell"},{"issue":"3","key":"10.1016\/j.amjmed.2022.04.029_bib0027","first-page":"226","article-title":"Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease","volume":"1","author":"Labandeira-Garcia","year":"2012","journal-title":"Am J Neurodegener Dis"},{"issue":"8","key":"10.1016\/j.amjmed.2022.04.029_bib0028","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.peptides.2005.03.010","article-title":"The AT2 receptor\u2013a matter of love and hate","volume":"26","author":"Steckelings","year":"2005","journal-title":"Peptides"},{"issue":"12","key":"10.1016\/j.amjmed.2022.04.029_bib0029","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson's disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol"},{"issue":"18","key":"10.1016\/j.amjmed.2022.04.029_bib0030","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1212\/WNL.0000000000002082","article-title":"Cerebral small vessel disease and incident parkinsonism","volume":"85","author":"van der Holst","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.amjmed.2022.04.029_bib0031","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3389\/fneur.2019.01020","article-title":"Small vessel disease","volume":"10","author":"Hakim","year":"2019","journal-title":"Front Neurol."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322003515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322003515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:27:31Z","timestamp":1757582851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322003515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0002934322003515"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.04.029","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Angiotensin Receptor Blockers with Incident Parkinson Disease in Patients with Hypertension: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}